β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain

Venishetty, Vinay Kumar; Samala, Ramakrishna; Komuravelli, Rojarani; Kuncha, Madhusudana; Sistla, Ramakrishna; Diwan, Prakash V.

doi:10.1016/j.nano.2012.08.004

Cited by 61 publications

(36 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various small molecules such as beta hydroxy butyric acid, folic acid, myristic acid etc. have been explored for their targeting abilities to the specific disease or organ (Beduneau et al 2007;Meng et al 2010;Sotiriou et al 2002;Venishetty et al 2013). These small molecules have high affinity for particular receptors that are over expressed on the cell membranes of diseased tissues.…”

Section: Introductionmentioning

confidence: 99%

p-Hydroxy benzoic acid-conjugated dendrimer nanotherapeutics as potential carriers for targeted drug delivery to brain: an in vitro and in vivo evaluation

et al. 2015

Self Cite

View full text Add to dashboard Cite

Dendrimers which are discrete nanostructures/nanoparticles are emerging as promising candidates for many nanomedicine applications. Ligandconjugated dendrimer facilitate the delivery of therapeutics in a targeted manner. Small molecules such as p-hydroxyl benzoic acid (pHBA) were found to have high affinity for sigma receptors which are prominent in most parts of central nervous system and tumors. The aim of this study was to synthesize pHBA-dendrimer conjugates as colloidal carrier for site-specific delivery of practically water insoluble drug, docetaxel (DTX) to brain tumors and to determine its targeting efficiency. pHBA, a small molecule ligand was coupled to the surface amine groups of generation 4-PAMAM dendrimer via a carbodiimide reaction and loaded with DTX. The conjugation was confirmed by 1 HNMR and FT-IR spectroscopy. In vitro release of drug from DTXloaded pHBA-conjugated dendrimer was found to be less as compared to unconjugated dendrimers. The prepared drug delivery system exhibited good physico-chemical stability and decrease in hemolytic toxicity. Cell viability and cell uptake studies were performed against U87MG human glioblastoma cells and formulations exerted considerable anticancer effect than plain drug. Conjugation of dendrimer with pHBA significantly enhanced the brain uptake of DTX which was shown by the recovery of a higher percentage of the dose from the brain following administration of pHBA-conjugated dendrimers compared with unconjugated dendrimer or formulation in clinical use (Taxotere Ò ). Therefore, pHBA conjugated dendrimers could be an efficient delivery vehicle for the targeting of anticancer drugs to brain tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

p-Hydroxy benzoic acid-conjugated dendrimer nanotherapeutics as potential carriers for targeted drug delivery to brain: an in vitro and in vivo evaluation

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…SLNs possess a solid lipid core matrix that is stabilized by surfactants. SLNs have been used as brain targeted delivery systems for many therapeutics, such as doxorubicin, 82 docetaxel, 83 quercetin, 84 atazanavir, 85 and quinine. 86 Nowadays, PEGylated SLNs have been widely investigated for brain drug delivery.…”

Section: Solid Lipid Nps (Slns)mentioning

confidence: 99%

Current approaches to enhance CNS delivery of drugs across the brain barriers

Lu¹,

Zhao²,

Wong³

et al. 2014

IJN

282

168

View full text Add to dashboard Cite

Although many agents have therapeutic potentials for central nervous system (CNS) diseases, few of these agents have been clinically used because of the brain barriers. As the protective barrier of the CNS, the blood–brain barrier and the blood–cerebrospinal fluid barrier maintain the brain microenvironment, neuronal activity, and proper functioning of the CNS. Different strategies for efficient CNS delivery have been studied. This article reviews the current approaches to open or facilitate penetration across these barriers for enhanced drug delivery to the CNS. These approaches are summarized into three broad categories: noninvasive, invasive, and miscellaneous techniques. The progresses made using these approaches are reviewed, and the associated mechanisms and problems are discussed.

show abstract

“…As a result, SLN have been used to deliver several therapeutic agents such as doxorubicin (Agarwal et al 2011), atazanavir (Chattopadhyay et al 2008), quinine (Gupta et al 2007), docetaxel (Venishetty et al 2013) and quercetin (Dhawan et al 2011) into the brain, as described in previous studies. Regarding the lipidic properties of SLN, it is expected that SLN easily enter into the brain tissues.…”

Section: Solid Lipid Npmentioning

confidence: 99%

Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis

Ghalamfarsa

Hojjat‐Farsangi

Mohammadnia‐Afrouzi

et al. 2016

Journal of Immunotoxicology

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized with immunopathobiological events, including lymphocytic infiltration into the central nervous system (CNS), microglia activation, demyelination and axonal degeneration. Although several neuroprotective drugs have been designed for the treatment of MS, complete remission is yet matter of debate. Therefore, development of novel therapeutic approaches for MS is of a high priority in immunological research. Nanomedicine is a recently developed novel medical field, which is applicable in both diagnosis and treatment of several cancers and autoimmune diseases. Although there is a marked progress in neuroimaging through using nanoparticles, little is known regarding the therapeutic potential of nanomedicine in neurological disorders, particularly MS. Moreover, the majority of data is limited to the MS related animal models. In this review, we will discuss about the brain targeting potential of different nanoparticles as well as the role of nanomedicine in the diagnosis and treatment of MS and its animal model, experimental autoimmune encephalomyelitis. ARTICLE HISTORY

show abstract

β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain

Cited by 61 publications

References 32 publications

p-Hydroxy benzoic acid-conjugated dendrimer nanotherapeutics as potential carriers for targeted drug delivery to brain: an in vitro and in vivo evaluation

p-Hydroxy benzoic acid-conjugated dendrimer nanotherapeutics as potential carriers for targeted drug delivery to brain: an in vitro and in vivo evaluation

Current approaches to enhance CNS delivery of drugs across the brain barriers

Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis

Contact Info

Product

Resources

About